Suppr超能文献

miR-9 和 miR-200 调控三阴性乳腺癌中 PDGFRβ 介导的肿瘤细胞内皮分化。

miR-9 and miR-200 Regulate PDGFRβ-Mediated Endothelial Differentiation of Tumor Cells in Triple-Negative Breast Cancer.

机构信息

Start Up Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Tumor Immunology Unit, Department of Health Sciences, University of Palermo, Palermo, Italy.

出版信息

Cancer Res. 2016 Sep 15;76(18):5562-72. doi: 10.1158/0008-5472.CAN-16-0140. Epub 2016 Jul 11.

Abstract

Organization of cancer cells into endothelial-like cell-lined structures to support neovascularization and to fuel solid tumors is a hallmark of progression and poor outcome. In triple-negative breast cancer (TNBC), PDGFRβ has been identified as a key player of this process and is considered a promising target for breast cancer therapy. Thus, we aimed at investigating the role of miRNAs as a therapeutic approach to inhibit PDGFRβ-mediated vasculogenic properties of TNBC, focusing on miR-9 and miR-200. In MDA-MB-231 and MDA-MB-157 TNBC cell lines, miR-9 and miR-200 promoted and inhibited, respectively, the formation of vascular-like structures in vitro Induction of endogenous miR-9 expression, upon ligand-dependent stimulation of PDGFRβ signaling, promoted significant vascular sprouting of TNBC cells, in part, by direct repression of STARD13. Conversely, ectopic expression of miR-200 inhibited this sprouting by indirectly reducing the protein levels of PDGFRβ through the direct suppression of ZEB1. Notably, in vivo miR-9 inhibition or miR-200c restoration, through either the generation of MDA-MB-231-stable clones or peritumoral delivery in MDA-MB-231 xenografted mice, strongly decreased the number of vascular lacunae. Finally, IHC and immunofluorescence analyses in TNBC specimens indicated that PDGFRβ expression marked tumor cells engaged in vascular lacunae. In conclusion, our results demonstrate that miR-9 and miR-200 play opposite roles in the regulation of the vasculogenic ability of TNBC, acting as facilitator and suppressor of PDGFRβ, respectively. Moreover, our data support the possibility to therapeutically exploit miR-9 and miR-200 to inhibit the process of vascular lacunae formation in TNBC. Cancer Res; 76(18); 5562-72. ©2016 AACR.

摘要

将癌细胞组织成内皮样细胞排列的结构以支持新血管生成并为实体瘤提供燃料是进展和不良预后的标志。在三阴性乳腺癌(TNBC)中,PDGFRβ 已被确定为该过程的关键参与者,被认为是乳腺癌治疗的有前途的靶点。因此,我们旨在研究 miRNA 作为抑制 TNBC 中 PDGFRβ 介导的血管生成特性的治疗方法的作用,重点研究 miR-9 和 miR-200。在 MDA-MB-231 和 MDA-MB-157 TNBC 细胞系中,miR-9 和 miR-200 分别促进和抑制了体外血管样结构的形成。在配体依赖性刺激 PDGFRβ 信号后,内源性 miR-9 的表达诱导,促进了 TNBC 细胞的显著血管发芽,部分通过直接抑制 STARD13 来实现。相反,miR-200 的异位表达通过直接抑制 ZEB1 间接降低 PDGFRβ 的蛋白水平来抑制这种发芽。值得注意的是,通过在 MDA-MB-231 异种移植小鼠中生成 MDA-MB-231 稳定克隆或肿瘤周围递送,体内 miR-9 抑制或 miR-200c 恢复强烈减少了血管腔隙的数量。最后,在 TNBC 标本中的 IHC 和免疫荧光分析表明,PDGFRβ 表达标记了参与血管腔隙的肿瘤细胞。总之,我们的结果表明,miR-9 和 miR-200 在调节 TNBC 的血管生成能力方面发挥相反的作用,分别作为 PDGFRβ 的促进剂和抑制剂。此外,我们的数据支持了通过治疗性利用 miR-9 和 miR-200 来抑制 TNBC 中血管腔隙形成的可能性。癌症研究;76(18);5562-72. ©2016 AACR.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验